Ceapro Inc.

Enabling Technologies

Enabling Technologies

Ceapro's proprietary enabling technologies make us the ideal partner for the identification, extraction, production and processing of unique active ingredients originating from natural sources.

Learn More
Cosmeceuticals

Cosmeceuticals

Ceapro's two value driving products, oat beta glucan and avenanthramides, are manufactured from Ceapro’s proprietary extraction technology and sold either as bulk active ingredients in many household names, cosmetic and personal care brands, (such as Aveeno, Burt’s Bees and Neutrogena) and as high end finished products through our JuventeDC product line.

Learn More
Nutraceuticals

Nutraceuticals

Ceapro is actively developing powder formulations of oat beta glucan and avenanthramides, which have proven health benefits, to expand into this growing market.

Learn More

PGX Technology

PGX technology is a novel spray drying technique for processing water-soluble biopolymers which utilizes the unique and tunable properties of Pressurized Gas eXpanded liquids.

Learn More About PGX
PGX Technology

Stock Information CZO

TSX Venture

CZO

Loading...

Change

Loading...

Volume

Loading...

Day Range

Loading...

52 Week Range

Loading...

Stock Information CRPOF

OTCQX Markets

CRPOF

Loading...

Change

Loading...

Volume

Loading...

Day Range

Loading...

52 Week Range

Loading...

CEO Interview

Gilles Gagnon, CEO of Ceapro provides Company overview and discusses how Ceapro is working on commercializing the "active ingredients" derived from oats and other renewable plant resources for healthcare and cosmetic industries.

Products

Ceapro isolates ingredients from oat products, such as Avenanthramides and Beta Glucan, and botanical products to naturally enhance popular cosmetic and personal care products.

View Our Products
Products

Latest News

Ceapro Inc. Reports 2023 Third Quarter and Nine-Month Financial Results and Operational Highlights
Nov 29, 2023 | Read More

Ceapro Inc. Initiates Phase 1-2a Study Assessing Its Flagship Product Avenanthramides for Potential Applications in Inflammation Based Diseases
Nov 27, 2023 | Read More

Ceapro Inc. Enters into Technical Collaboration with NATEX Prozesstechnologie GmbH and Provides Update on the Scale-Up Project for its Patented Pressurized Gas eXpanded (PGX) Technology
Nov 7, 2023 | Read More

Ceapro Inc. Reports 2023 Second Quarter and Six-Month Financial Results and Provides Corporate Update
Aug 29, 2023 | Read More

View All News